Suat PAKER, Füsun ATLIHAN, Pamir GÜLEZ, Canan VERGİN, Alpay ÖZBEK

The efficacy of monodose varicella vaccine in pediatric cancer patients

Bu çalışmada tek doz suçiçeği aşısının etkinliği akut lenfoblastik lösemili ve lenfomalı 20 hastada değerlendirildi. Tüm hastalarda antivarisella antikorları negatif idi. Tüm olgular en azından 6 ay süre ile remisyonda idiler ve aşının yapıldığı günkü lenfosit sayıları 700/mm3 ve üzerinde idi. idame tedavisi alan hastalarda aşıdan 1 hafta öncesinden, 1 hafta sonrasına kadar kemoterapiye ara verildi. Antivarisella antikor tayinleri aşıdan 3 ve 24 ay sonra antikor yanıtının belirlenmesi amacıyla elde edildi. Kanser grubunda antivarisella antikor geometrik ortalaması 3. ayda 42.8 HU ve 24. ayda 29.3 olarak bulundu. Kontrol grubunda ise bu değerler sırasıyla 42.3 ve 31.8 HU idi. Her iki grupta da 3 ve 24. aylardaki seropozitivite oranları %90 olarak belirtendi. Suçiçeği aşısına bağlı ciddi olmayan yan etkiler hasta grubunda %40, kontrol grubunda ise%10 olarak belirlendi. Sonuç olarak tek doz varisella aşısının akut lenfoblastik lösemili ve lenfomalı olgularda etkin ve güvenli olduğunu söyleyebiliriz.

Anahtar Kelimeler:

Lenfom, Su çiçeği aşısı, Çocuk, Bağışıklama, Lösemi, lenfositik, akut

Kanserli hastalarda tek doz suçiçeği aşısının etkinliği

In this study the efficacy of a single dose varicella vaccine was evaluated in 20 patients with acute lymphoblastic leukemia and lymphoma. All patients were serologically negative by the absence of antivaricella antibody. All cases were in remission for at least 6 months and their absolute lymphocyte count at the time of immunization was > 700/mm3. For patients receiving maintenance therapy, chemotherapy was suspended for 1 week before and 1 week after immunization. Antivaricella antibody concentration was determined 3 and 24 months after immunization to evaluate antibody response. In cancer group geometric mean antibody concentration was found 42.78 HU on the 3"* month and 29.3 HU on the 24th month and in the control group the values were 45.98 HU and 31.8. The seropositivity rates were found 90% on the 3rd and on the 24th months in each group. Unserious side effects due to varicella vaccination were determined in 40% of the pédiatrie cancer group and in 10% of the control group. In conclusion we can say that single dose varicella vaccine is effective and safe in patients with acute lymphoblastic leukemia and lymphoma.

Keywords:

Lymphoma, Chickenpox Vaccine, Child, Immunization, Leukemia, Lymphocytic, Acute,

PDF

___

1. Yung LS. Infection in cancer patients. In: Haskell MC ed. Cancer treatment 4th ed. Philadelphia. WB Saunders, 1995:206-210.
2. Bunell PA. Varicella zoster infections. In: Feign RD, Cherry JD eds. Pediatric Infectious Disease 3rd ed. Vol.2. Philadelphia. WB Saunders, 1992:1587-1591.
3. Coo PW, Donahue JG, Manşon JE, et al. The epidemiology of varicella and its complications. J Inf Dis 1995; 172:706-12.
4. Drwal-Klein LA, O'Donovan CA. Varicella in pediatric patients. Ann Pharmacother 1993;27:938-47.
5. Asano Y , Nagai T, Miyato T, et al. Long term protective immunity of recepients of the Oka strain of live varicella vaccine. Pediatrics. 1985:75:667-671.
6. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2 year efficacy study and 7 year follow up study. Vaccine. 1991;9:643-647.
7. Begue P. Varicella vaccine. Arch Pediatr 1999:6:1005-9.
8. Asano Y. Varicella vaccine: The Japanese experience. J Inf Dis 1996;174:S310-3.
9. Arbeter AM, Granowetter L, Starr SE, et al. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 1990;85;338-44.
10. Takahashi M, Kamiya H, Baloa K, et al. Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J. 1985;61:61- 67.
11. Morales-Castillo ME, Alvarez-Munos MT, Solorzano-Santos F, et al. Live varicella vaccine in both immunocompromised and healthy children. Arch Med Res 2000;31:85-7.
12. Gershon AA, Steinberg S, Gelb L, et al. A multicenter trial of live attenuated varicella vaccine in children with leukemia in remission. Postgrad Med J. 1985;61:73-8.
13. Ecevit Z, Büyükpamukçu M, Kanra G, et al. Oka strain live varicella vaccine in children with cancer. Pediatr Infect Dis J. 1996:15:169-170.
14. Lu, Tan AM, Tan CK. Experience of varicella vaccination in acute lymphoblastic leukemia. Singapore Med J 1996;37:607-10.
15. Nvajas A, Astigarraga I, Femandez-Teijeiro A, et al. Vaccination of chickenpox in children with acute lymphoblastic leukemia. Enferm Infec Microbiol Clin 1999; 17:162-5.
16. La Russa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis. 1996; 174:320-323.
17. Gershon AA, La Russa P, Steinberg S. The varicella vaccine. Clinical trials in immunocompromised individuals. Infect Dis Clin North Am. 1996:10:583-594.